Skip to content
Community, Medical Health Aged Care

Charity launches national movement to spotlight Australia’s dangerously ‘SLOW’ response to heart valve disease

Hearts4heart 3 mins read

MEDIA RELEASE

Monday, 16 February 2026: Australia’s response to heart valve disease is moving dangerously slowly, putting hundreds of thousands of lives at risk. To help change that, leading heart charity, Hearts4heart is launching the nation’s first ‘SLOW Symptoms’ campaign during Heart Valve Disease Awareness Week (16–22 February 2026).

In 2021, an estimated 600,000 Australians were living with diagnosed heart valve disease, with a further 254,000 people unaware they had the condition, meaning an estimated 850,000 Australians may already be affected.1,2

Australian and global heart health advocates now warn heart valve disease is “the next cardiac epidemic”, driven by an ageing population and persistently low awareness. Global projections suggest the number of people living with heart valve disease will double by 2040 and triple by 2060. Applied to Australia, this could mean up to 1.7 million Australians living with heart valve disease by 2040 if urgent action is not taken.2-4

Despite its growing prevalence, a persistently slow response to heart valve disease is sustaining low public understanding driving the tendency to misattribute symptoms as signs of ageing. This leads to delayed diagnosis, missed treatment opportunities and avoidable complications such as heart failure, stroke, arrhythmia and premature death.3,5

This week, Hearts4heart is launching the SLOW Symptoms campaign in Australia, a simple and memorable tool developed by UK charity Heart Valve Voice. With their support, the campaign is being introduced locally to help Australians recognise the red-flag symptoms of heart valve disease and seek early medical advice. 

SLOW stands for: 

  • Shortness of breath
  • Lightheadedness on exertion 
  • Feeling Older than your years 
  • Weary or unusually fatigued 

Much like the FAST campaign for stroke, SLOW aims to embed these warning signs into everyday language, while also reflecting the slow pace of Australia’s response to the disease. 

Hearts4heart CEO and Founder Tanya Hall said the SLOW campaign was a critical step in closing Australia’s awareness gap. 

“Too many Australians are living with heart valve disease without knowing it, and by the time they do, it can be too late,” said Ms Hall.

“The SLOW campaign gives people the language to recognise symptoms, start a conversation with their GP and ask for a stethoscope check. If we don’t speed up Australia’s response, the human and health system costs will be enormous.”

If detected early, heart valve disease can be effectively monitored and treated, significantly improving quality of life and survival. However, outcomes for people with untreated, severe heart valve disease are poor, with more than half of symptomatic patients with severe aortic stenosis dying within two years if left untreated.

“Heart valve disease is one of the most under-recognised and under-diagnosed heart conditions we see,” said Professor David Playford, Professor of Cardiology at the University of Notre Dame.

“Heart valve disease gets worse before symptoms develop, and early symptoms such as breathlessness may be ignored or assumed to be due to age or lack of fitness. A simple stethoscope check followed by an echocardiogram is the best way to diagnose heart valve disease. Earlier detection saves lives.”

Throughout February, Hearts4heart will also deliver free heart health checks in select locations in Melbourne and Perth, helping Australians identify early warning signs and access timely specialist care.

Australians are encouraged to learn the SLOW symptoms, attend a free screening event if eligible, and speak to their GP about a stethoscope check, particularly if they are over 65 or experiencing unexplained breathlessness or fatigue.

For more information about Heart Valve Disease Awareness Week, the SLOW Symptoms campaign or free screening events, visit www.hearts4heart.org.au. 

 

ENDS  

Media contacts: 

 

Roberta Sowden

Palin Communications  

[email protected] 

0418 842 104 

 

Kerry Jung

Palin Communications  

0435 753 618

About Hearts4heart

Hearts4heart is a non-profit organisation that supports, educates, and advocates for people with heart disease in Australia and New Zealand. Hearts4heart works to eliminate stroke and preventable deaths and improve the quality of life for patients and caregivers. 

Bringing together patients and healthcare professionals to reduce the burden of heart disease, Hearts4heart provides targeted educational programs, resources, and services to improve diagnosis, treatment, and quality of life. To find out more visit www.hearts4heart.org.au  

References 

  1. Playford D, Stewart S, Harris SA, et al. Mortality associated with moderate and severe mitral regurgitation in 608 570 men and women undergoing echocardiography. Heart 2024:heartjnl-2024-324790. DOI: 10.1136/heartjnl-2024-324790. 
  2. Hearts4heart. Heart Valve Disease. 
  3. Global Heart Hub. HEART VALVE DISEASE: Harnessing Innovation to Save Lives, Mitigate Costs, and Advance the Healthy Aging Agenda. March 2023. Available at: https://globalhearthub.org/wp-content/uploads/2023/03/Position-Paper-on-HVD-and-the-Healthy-Aging-Agenda.pdf 
  4. Playford D, Ihdayhid AR, Guilbert-Wright P. Identifying Gaps in Detection of Heart Valve Disease in Australia: A Population Survey. Heart Lung Circ 2025;34(2):162-172. (In eng). DOI: 10.1016/j.hlc.2024.10.019. 
  5. Strange G, Scalia GM, Playford D, Simon S. Uncovering the treatable burden of severe aortic stenosis in Australia: current and future projections within an ageing population. BMC Health Serv Res 2021;21(1):790. (In eng). DOI: 10.1186/s12913-021-06843-0. 
 
 

More from this category

  • General News, Medical Health Aged Care
  • 16/02/2026
  • 06:00
CSL Seqirus

neffy®, adrenaline nasal spray, now approved to treat anaphylaxis in Australia

Melbourne, 16 February 2026 CSL Seqirus, part of leading Australian biotechnology company CSL, has today announced that neffy® adrenaline (epinephrine) nasal spray is now available and has been approved for use in Australia for the emergency treatment of anaphylaxis in adults and children 15kg+ and aged four years and over.1 Anaphylaxis occurs after exposure to an allergen, such as food, medications and insect bites and stings, and can be life threatening if not immediately treated with adrenaline.3 Adrenaline rapidly reverses the effects of the condition by reducing throat swelling, opening the airways, and maintaining heart function and blood pressure.3 Anaphylaxis…

  • Medical Health Aged Care
  • 16/02/2026
  • 06:00
Vertex

Vertex Announces Reimbursement for ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) in Australia, a new once-daily next-in-class Treatment for People with Cystic Fibrosis

ALYFTREK®is now reimbursed for Australians with cystic fibrosis (CF) aged 6 years and older with at least one responsive mutation – Approximately 3,200 Australians living with CF are now able to access this next-in-class treatment[i] – SYDNEY, Sunday 15th February 2026 – Vertex Pharmaceuticals today announced that as of 1 February 2026, ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) will be funded on the Pharmaceutical Benefits Scheme (PBS) for the treatment of people aged 6 years and older with cystic fibrosis (CF) and who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is considered responsive, based on clinical…

  • Community, Entertainment
  • 14/02/2026
  • 11:09
City of Sydney

Sydney Lunar Streets Picture/Vision Op TONIGHT

WHAT: From Chinatown to Thaitown, the laneways of Haymarket light up for an unforgettable street festival to welcome in the Year of the Horse.…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.